Sanara MedTech (SMTI) Expected to Release Quarterly Earnings on Wednesday

Sanara MedTech (NASDAQ:SMTI – Get Free Report) is projected to issue its Q3 2026 resultson Wednesday, November 11th. Analysts expect the company to announce earnings of $0.06 per share and revenue of $29.30 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Monday, November 16, 2026 at 4:00 PM ET.

Sanara MedTech (NASDAQ:SMTI – Get Free Report) last released its earnings results on Tuesday, August 11th. The company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.03). The firm had revenue of $28.14 million during the quarter, compared to analysts’ expectations of $28.95 million. Sanara MedTech had a positive return on equity of 29.72% and a negative net margin of 29.15%.

Sanara MedTech Stock Up 1.7%

SMTI opened at $32.10 on Tuesday. Sanara MedTech has a 12 month low of $16.05 and a 12 month high of $35.52. The business has a 50-day moving average of $34.20 and a two-hundred day moving average of $25.79. The company has a debt-to-equity ratio of 5.86, a current ratio of 2.58 and a quick ratio of 2.30. The stock has a market capitalization of $295.00 million, a price-to-earnings ratio of 146.96 and a beta of 1.23.

Wall Street Analyst Weigh In

Several equities research analysts have commented on SMTI shares. Weiss Ratings upgraded Sanara MedTech from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. HC Wainwright lowered Sanara MedTech from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $36.00 to $35.00 in a research note on Thursday, July 30th. Lake Street Capital cut Sanara MedTech from a “buy” rating to a “hold” rating and set a $35.00 target price for the company. in a report on Thursday, July 30th. Freedom Capital downgraded shares of Sanara MedTech from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 3rd. Finally, Wall Street Zen downgraded shares of Sanara MedTech from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 1st. Four equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Reduce” and a consensus target price of $35.00.

Get Our Latest Stock Report on SMTI

Sanara MedTech Company Profile

(Get Free Report)

Sanara MedTech Inc is a medical technology company focused on developing, commercializing and distributing products used in wound care, surgical soft-tissue repair and tissue regeneration. The company serves healthcare providers treating acute, chronic and complex wounds, as well as patients requiring surgical tissue management.

Sanara’s product portfolio includes advanced wound-care and tissue-repair technologies such as CellerateRX products, FORTIFY tissue-repair products and other regenerative medicine solutions.

See Also

Earnings History for Sanara MedTech (NASDAQ:SMTI)

Receive News & Ratings for Sanara MedTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanara MedTech and related companies with MarketBeat.com's FREE daily email newsletter.